Skip to content
healthcare.dev

Harvoni

NDC 61958-1804, ledipasvir and sofosbuvir, pellet, from Gilead Sciences, Inc.

Product NDC
61958-1804
Status
Listed
Labeler
Gilead Sciences, Inc
Dosage form
PELLET
Route
ORAL
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
NDA
Application
NDA212477
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/61958-1804 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • LEDIPASVIR45 mg/1
  • SOFOSBUVIR200 mg/1

Pharmacologic classes

Breast Cancer Resistance Protein Inhibitors [MoA]; Hepatitis C Virus NS5A Inhibitor [EPC]; Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]; P-Glycoprotein Inhibitors [MoA]; RNA Replicase Inhibitors [MoA]

Package NDCNDC-11Package
61958-1804-161958180401120 PELLET in 1 PACKET (61958-1804-1)

Linked data

RxNorm, label and prices

RxNorm concepts

Related lookups

  • FDA label sections

    GET /v1/drugs/labels/f4ec77e4-bae8-4db0-b3d5-bde09c5fa075

Use it

Look up 61958-1804 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/61958-1804 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 61958-1804. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.